Skip to main content
  • Other Publications
  • Subscribe
  • Contact Us
Advertisement
JCORE Reference
this is the JCORE Reference site slogan
  • Home
  • Most Read
  • About Us
    • About Us
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Patients
  • Reference Site Links
    • View Regions
  • Archive

A Special Regenerative Rehabilitation and Genomics Letter: Is There a “Hope” Molecule?

Cristy Phillips, Ahmad Salehi
DOI: 10.2522/ptj.2016.96.4.581 Published 1 April 2016
Cristy Phillips
C. Phillips, PT, EdD, Department of Physical Therapy, Arkansas State University, PO Box 910, Jonesboro, AR 72467 (USA).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmad Salehi
A. Salehi, MD, PhD, VA Palo Alto Health Care System, Palo Alto, California, and Department of Psychiatry and Behavioural Sciences, Stanford University School of Medicine, Stanford, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

We are delighted to see the dedication of a special series to regenerative rehabilitation and genomics. There is no doubt that an increased focus on genetically driven responses to injury, disease, and aging will enhance prevention and treatment efforts for a number of conditions. Among those well-positioned to benefit from this progress are individuals with mood disorders, which has prompted us to alert our colleagues about recent progress in elucidating the molecular mechanisms that underlie musculoskeletal and central nervous system interdependence, knowledge that may be deployed to prevent and treat stress-related depression in the near future.

Depression is a pervasive health problem that includes emotional, psychomotor, cognitive, and biorhythmic disturbances. Current estimates suggest that this disorder has a 1-year prevalence of 9% of the US population.1 Of those affected, 42% report severe functional impairments; in contrast, 24% of people with chronic medical disorders report severe functional impairment, underscoring a significantly higher degree of impairment for those with mood disorders.2 Depressive symptoms are associated with a higher risk of all-cause mortality3–6 and a 20-fold increase in the risk of suicide.7 Approximately half of patients with pain in the physical therapy setting demonstrate symptoms of depression.8,9 Notably, depression is expected to be the second-greatest health burden in terms of quality-adjusted life-years by 2020.10 The direct and indirect costs of treating depression are staggering, amounting to $44 billion annually in the United States.11 Limited accessibility to effective treatment options contribute to the exorbitant human and financial toll of major depression,2,12 prompting us and others to acknowledge the need for a diversification of efforts to find feasible and effective treatment options.12–14

Physical exercise has been suggested as a promising means of complementary care for the treatment of depression.15,16 Epidemiological and clinical research demonstrates that exercise reduces risk for mood disorders,17–19 degree of symptoms,20 and incidence of relapse.21,22 The putative effects of exercise include optimization of levels of neurotransmitters,23 neurotrophic factors,23–25 β–endorphins,26,27 cortisol,28,29 and growth hormone.30 Moreover, recent ground-breaking work on mice has demonstrated that a muscle-derived protein (peroxisome proliferator-activated receptor C coactivator 1α [Pgc-1α]*) elicited by exercise can directly influence mood by altering brain mechanisms involved in depression.31

It has long been known that physical exercise increases levels of PGC-1α.32,33 This knowledge, along with the fact that PGC-1α can significantly influence brain physiology, led to the suggestion of a direct linkage of PGC-1α to depression.31 Nevertheless, deriving scientific proof of this link has proven onerous because PGC-1α is expressed in a variety of systems throughout the body (eg, musculoskeletal, cardiovascular, hematopoietic, digestive, nervous), making it difficult to discern whether the effects of exercise originate from central or peripheral mechanisms. To tackle this problem, Agudelo and colleagues used mice that were genetically modified to produce excessive levels of Pgc-1α in their type II skeletal muscle fibers.31 The mice were then exposed to chronic stress—a method known to induce depression. Interestingly, mice overexpressing Pgc-1α in their muscles were far more resistant to depressive symptoms in comparison with mice with normal levels of Pgc-1α. The researchers then questioned what would happen if Pgc-1α levels were reduced. Mice genetically engineered to produce lower levels of Pgc-1α in their skeletal muscles were subjected to a forced-swim test. After a significant amount of stress, the mice appeared to “lose hope,” as evidenced by their decreased survival efforts during forced swimming (an indicator of depression). Altogether, these results suggest that the release of “hope molecules” from the skeletal muscles of rodents influence mood disorder symptoms. What remains to be determined is how a peripheral molecule such as Pgc-1α can drastically influence mechanisms within the brain. Although these authors suggested that central mechanisms involving kynurenine metabolism are involved, it also seems plausible that increases in Pgc-1α expression may alter levels of neurotrophins (brain-derived neurotrophic factor) within the brain and contribute to changes in structure and function (see Phillips et al34), leading to a reduction in depressive symptoms.

To date, the aforementioned work has not been extended to patient populations with depression. Nevertheless, the work provides a strong theoretical basis for the idea that endurance exercise can be used to induce the release of PGC-1α from skeletal muscles to mitigate depressive symptoms. So the question arises as to whether there is currently enough evidence to support the deployment of physical activity to positively influence depressive symptoms in clinical populations. To answer this long-standing question, Cooney and colleagues conducted a meta-analysis of high-quality randomized trials published up to March 2013.15 Thirty-nine studies with a total of 2,326 participants were included in the review. The authors reported that exercise produced effects comparable to treatment by either antidepressive medications or psychotherapy. A meta-analytic study by Silveira and colleagues also demonstrated that aerobic exercise moderately reduced the signs of depression, with populations over 60 years of age deriving the greatest effect.16 Notwithstanding, there is currently little evidence to indicate which modality of exercise is optimal (aerobic, strengthening, flexibility, or combinations). In a recent meta-analytic review, Stanton and Reaburn tried to determine optimal parameters for using exercise to treat depression (eg, frequency, intensity, duration, and type of exercise). All 5 randomized controlled studies meeting inclusion criteria were aerobic in nature (walking on treadmill or outdoors, cycling on a stationary bike, or training on an elliptical machine).35 Positive evidence was found that aerobic exercise of moderate intensity, undertaken 3 times weekly for a minimum of 9 weeks, was successful in treating depression.35

Clearly, large-scale, multiple-site clinical investigations that study the relationship between exercise and depression are needed. The effects of Pgc-1α on phenotypic traits—such as adiposity, lean mass, and fasting glucose—and the way that they could be modulated by genetic background (ethnicity) have not been precisely understood. Moreover, the degree to which Pgc-1α polymorphisms (common variation in gene sequence) determine an individual's response is unknown. Future work that combines these measures with neuroimaging studies should be used to determine optimal “doses” of physical intervention across patient populations. Finally, strategies for overcoming core symptoms of depression—such as loss of interest, motivation, and energy; generalized fatigue; low self-worth feelings and low self-confidence; psychosomatic complaints; and comorbid health problems—need to be clearly delineated and articulated so that exercise adherence can be optimized.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

A large body of evidence has indicated the importance of PGC-1a in a number of important biological processes. The figure suggests a role for PGC-1a in mood disorders, but this molecule also affects other key physiological processes. For instance, through acting on a number of intermediate molecules, PGC-1a plays a vital role in the maintenance of metabolic (glycogen synthesis), skeletal muscle (mitochondrial biogenesis), and cognitive functions (trophic factor release). Reciprocal interactions exist among these variables, suggesting that physical activity could play a role in therapeutic strategies that target mood, metabolic, and cognitive disorders. PGC-1a=peroxisome proliferator-activated receptor C coactivator 1α, BDNF=brain-derived neurotrophic factor, FNDC5=fibronectin type III domain-containing protein 5, NAD (+)=nicotinamide adenine dinucleotide, FBX2=F-box protein 2, NMDARs=N-methyl-D-aspartate receptors, GluN2a=glutamate receptor subunit 2a, GluN2b=glutamate receptor subunit 2b, GluA1=glutamate receptor-A1, GluA2=glutamate receptor-A2, AMPARs=α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, TNF-a=tumor necrosis factor alpha, IL-6=interleukin 6, IGF-1=insulin-like growth factor 1, GLP-1=glucagon-like peptide-1.

We contend that the aforementioned findings can be used to enrich practice and research across a number of settings, as mental and physical health are inextricably melded. Indeed, there is evidence that physical activity can be used to fundamentally change brain physiology in people with cognitive, neurodegenerative, and mood disorders.31,35 Moreover, the fact that depressive symptoms exert a significant influence on service utilization36 and clinical outcomes8 makes it imperative for physical therapists to stay abreast of emerging knowledge that links the reciprocal relationship between skeletal muscle activity and brain function. Doing so will ensure that we may remain steadfast in our mission to provide evidence-based practice, in conjunction with other specialists, for all people, including those with depression.

Footnotes

  • ↵* All capital letters are used when discussing human (PGC-1α) genes or proteins, whereas only the first letter is capitalized when referring to rodent (Pgc-1α) genes or proteins. Genes are italicized (PGC-1α), whereas proteins are not italicized (PGC-1α).

  • © 2016 American Physical Therapy Association

References

  1. ↵
    Centers for Disease Control & Prevention. Current depression among adults–United States, 2006 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59:1229–1235.
    OpenUrlPubMed
  2. ↵
    1. Druss BG,
    2. Hwang I,
    3. Petukhova M,
    4. et al
    . Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2009;14:728–737.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Whang W,
    2. Kubzansky LD,
    3. Kawachi I,
    4. et al
    . Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol. 2009;53:950–958.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Lett HS,
    2. Blumenthal JA,
    3. Babyak MA,
    4. et al
    . Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305–315.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Penninx BW,
    2. Beekman AT,
    3. Honig A,
    4. et al
    . Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58:221–227.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Schulz R,
    2. Drayer RA,
    3. Rollman BL
    . Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry. 2002;52:205–225.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Lépine JP,
    2. Briley M
    . The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7(suppl 1):3–7.
    OpenUrlPubMed
  8. ↵
    1. Bair MJ,
    2. Robinson RL,
    3. Katon W,
    4. Kroenke K
    . Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–2445.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Lundberg M,
    2. Larsson M,
    3. Ostlund H,
    4. Styf J
    . Kinesiophobia among patients with musculoskeletal pain in primary healthcare. J Rehabil Med. 2006;38:37–43.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Murray CJ,
    2. Lopez AD
    . Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Stewart WF,
    2. Ricci JA,
    3. Chee E,
    4. et al
    . Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135–3144.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Baghai TC,
    2. Möller HJ,
    3. Rupprecht R
    . Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharma Des. 2006;12:503–515.
    OpenUrlCrossRef
  13. ↵
    1. Ghasemi M,
    2. Phillips C,
    3. Trillo L,
    4. et al
    . The role of NMDA receptors in the pathophysiology and treatment of mood disorders. Neurosci Biobehav Rev. 2014;47:336–358.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Machado-Vieira R,
    2. Salvadore G,
    3. Luckenbaugh DA,
    4. et al
    . Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69:946–958.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Cooney GM,
    2. Dwan K,
    3. Greig CA,
    4. et al
    . Exercise for depression. Cochrane Database Syst Rev. 2013;9:CD004366.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Silveira H,
    2. Moraes H,
    3. Oliveira N,
    4. et al
    . Physical exercise and clinically depressed patients: a systematic review and meta-analysis. Neuropsychobiology. 2013;67:61–68.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. aan het Rot M,
    2. Collins KA,
    3. Fitterling HL
    . Physical exercise and depression. Mt Sinai J Med. 2009;76:204–214.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Abu-Omar K,
    2. Rütten A,
    3. Lehtinen V
    . Mental health and physical activity in the European Union. Soz Praventivmed. 2004;49:301–309.
    OpenUrlPubMed
  19. ↵
    1. Motl RW,
    2. Birnbaum AS,
    3. Kubik MY,
    4. Dishman RK
    . Naturally occurring changes in physical activity are inversely related to depressive symptoms during early adolescence. Psychosom Med. 2004;66:336–342.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Mead GE,
    2. Morley W,
    3. Campbell P,
    4. et al
    . Exercise for depression. Cochrane Database Syst Rev. 2009;3:CD004366.
    OpenUrlPubMed
  21. ↵
    1. Babyak M,
    2. Blumenthal JA,
    3. Herman S,
    4. et al
    . Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000;62:633–638.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Hoffman BM,
    2. Babyak MA,
    3. Craighead WE,
    4. et al
    . Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med. 2011;73:127–133.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Winter B,
    2. Breitenstein C,
    3. Mooren FC,
    4. et al
    . High impact running improves learning. Neurobiol Learn Mem. 2007;87:597–609.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Neeper SA,
    2. Gómez-Pinilla F,
    3. Choi J,
    4. Cotman CW
    . Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res. 1996;726:49–56.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Russo-Neustadt AA,
    2. Alejandre H,
    3. Garcia C,
    4. et al
    . Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology. 2004;29:2189–2199.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Di Luigi L,
    2. Guidetti L,
    3. Baldari C,
    4. Romanelli F
    . Heredity and pituitary response to exercise-related stress in trained men. Int J Sports Med. 2003;24:551–558.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Schwarz L,
    2. Kindermann W
    . Beta-endorphin, catecholamines, and cortisol during exhaustive endurance exercise. Int J Sports Med. 1989;10:324–328.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Traustadóttir T,
    2. Bosch PR,
    3. Cantu T,
    4. Matt KS
    . Hypothalamic-pituitary-adrenal axis response and recovery from high-intensity exercise in women: effects of aging and fitness. J Clin Endocrin Metab. 2004;89:3248–3254.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Mastorakos G,
    2. Pavlatou M,
    3. Diamanti-Kandarakis E,
    4. Chrousos GP
    . Exercise and the stress system. Hormones. 2005;4:73–89.
    OpenUrlPubMed
  30. ↵
    1. Luger A,
    2. Watschinger B,
    3. Deuster P,
    4. et al
    . Plasma growth hormone and prolactin responses to graded levels of acute exercise and to a lactate infusion. Neuroendocrinology. 1992;56:112–117.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Agudelo LZ,
    2. Femenía T,
    3. Orhan F,
    4. et al
    . Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell. 2014;159:33–45.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Irrcher I,
    2. Adhihetty PJ,
    3. Joseph AM,
    4. et al
    . Regulation of mitochondrial biogenesis in muscle by endurance exercise. Sports Med. 2003;33:783–793.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Russell AP,
    2. Feilchenfeldt J,
    3. Schreiber S,
    4. et al
    . Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes. 2003;52:2874–2881.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Phillips C,
    2. Baktir MA,
    3. Das D,
    4. et al
    . The link between physical activity and cognitive dysfunction and Alzheimer disease. Phys Ther. 2015;95:1046–1060.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Stanton R,
    2. Reaburn P
    . Exercise and the treatment of depression: a review of the exercise program variables. J Sci Med Sport. 2014;17:177–182.
    OpenUrlCrossRefPubMed
  36. ↵
    1. George SZ,
    2. Coronado RA,
    3. Beneciuk JM,
    4. et al
    . Depressive symptoms, anatomical region, and clinical outcomes for patients seeking outpatient physical therapy for musculoskeletal pain. Phys Ther. 2011;91:358–372.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Vol 96 Issue 4 Table of Contents
Physical Therapy: 96 (4)

Issue highlights

  • Confidence and Fear of Falling Avoidance Behavior in Older Adults
  • Reliability of the ECHOWS Tool
  • Functional Gait Assessment in Older Adults
  • Community-Based Exercise for People With Stroke
  • Knee Osteoarthritis and Promoting Exercise Adherence
  • Test Comparisons in Predicting Falls in Parkinson Disease
  • Scapular Position Using the Protractor Method
  • Physical Activity and Physical Fitness in Autism
  • Disability and Active Video Gaming
  • BNDF Genotype and Brain Function After Stroke
  • Electrodiagnostic Evaluation and Individuals With Volumetric Muscle Injury
  • Regenerative Rehabilitation and Advanced Technologies in Physical Therapy
  • Physical Therapists and Mechanotherapy
  • Translating Genomic Advances to Physical Therapist Practice
Email

Thank you for your interest in spreading the word on JCORE Reference.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Special Regenerative Rehabilitation and Genomics Letter: Is There a “Hope” Molecule?
(Your Name) has sent you a message from JCORE Reference
(Your Name) thought you would like to see the JCORE Reference web site.
Print
A Special Regenerative Rehabilitation and Genomics Letter: Is There a “Hope” Molecule?
Cristy Phillips, Ahmad Salehi
Physical Therapy Apr 2016, 96 (4) 581-583; DOI: 10.2522/ptj.2016.96.4.581

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Download Powerpoint
Save to my folders

Share
A Special Regenerative Rehabilitation and Genomics Letter: Is There a “Hope” Molecule?
Cristy Phillips, Ahmad Salehi
Physical Therapy Apr 2016, 96 (4) 581-583; DOI: 10.2522/ptj.2016.96.4.581
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • On “Benka Wallén M, Sorjonen K, Löfgren N, Franzén E. Structural validity of the Mini-Balance Evaluation Systems Test (Mini-BESTest) in people with mild to moderate Parkinson disease.” Phys Ther. 2016;96:1799–1806.
  • Author Response
  • Author Response
Show more Letters and Responses

Subjects

  • Special Series and Special Issues
    • Special Series on Regenerative Rehabilitation and Genomics
  • Intervention
    • Therapeutic Exercise
  • Psychosocial
    • Psychosocial: Other
  • Other Diseases/Conditions
    • Other Diseases or Conditions

Footer Menu 1

  • menu 1 item 1
  • menu 1 item 2
  • menu 1 item 3
  • menu 1 item 4

Footer Menu 2

  • menu 2 item 1
  • menu 2 item 2
  • menu 2 item 3
  • menu 2 item 4

Footer Menu 3

  • menu 3 item 1
  • menu 3 item 2
  • menu 3 item 3
  • menu 3 item 4

Footer Menu 4

  • menu 4 item 1
  • menu 4 item 2
  • menu 4 item 3
  • menu 4 item 4
footer second
footer first
Copyright © 2013 The HighWire JCore Reference Site | Print ISSN: 0123-4567 | Online ISSN: 1123-4567
advertisement bottom
Advertisement Top